Inhibition of the p53-hdm2 interaction with low molecular weight compounds.
The hdm2 protein, upon binding to p53, inhibits its tumor suppressor activity. The inhibition of the p53-hdm2 interaction represents therefore a new therapeutic strategy to activate wild type p53 in tumors. Potent low molecular weight compounds inhibiting this protein-protein interaction, which are active in vivo, have just been identified. This offers new perspectives and hopes in this research area.